Overview

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Estradiol
Fulvestrant